Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trade/Invest with Options Jerry a Point & Figure Chartist -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Olson who wrote (4687)	12/29/2001 8:39:34 PM
From: 2MAR$	Read Replies (2) \| Respond to of 5893

IMCL gets told by FDA to take a chill pill , delays their cancer drug Erbitux application till at least the third Qtr of 2002 ,,while the review clinical data ... Biotech hopes always want to rebound and continue to grow but leave less room for failure or postponement...and just as the little Santa rally starts them off IMCL gets chopped . Still a bit early for any tremendous break-thrus which looks like more into 2003-05 before they bring focussed new drugs into the pipeline that are really significant. According to Thomas Metcalfe , senior vice-pres at La Roche: ""We believe that the medical benefits of genomics are going to be felt in diagnostics some considerable time before they are felt in therapeutics......The consensus view is that genomics applications in diagnostics will be worth at least $3 billion to $5 billion sometime before 2010." forbes.com AFFX's marketcap is 1/2 of that right now <g> Really exciting stuff, but for now I want AFFX to develope some complications and do another MNLM for me and pullback significantly ...was following a feeling friday , wished I'd picked on IMCL though . Market giveth and taketh away... Pressure on the BTK for monday ...